AUTHORS
Steven Grzegorski, MD,PhD, Steven King, MD, MEd2, Xiaowen Kong, MA3, Josh Errickson, N/A4, Mona A Ali, PharmD5, Deborah DeCamillo, RN, BSN6, Stephanie Edwin, PharmD7, Christopher Giuliano, PharmD, MPH8, Nghi Ha, PharmD9, Brian Haymart, RN, MS10, Stephanie Hoffman, MD11, Scott Kaatz, DO, MSc12, Gregory Krol, MD13, Noelle Ryan, PharmD14, Suman Sood, MD15, Geoffrey Barnes, MD16, James Froehlich, MD, MPH17, Jordan K Schaefer, MD, MSc18
AFFILIATIONS
1 University of Michigan, Ann Arbor, United States
2 University of Michigan, Ann Arbor, United States
3 University of Michigan, Ann Arbor, United States
4 University of Michigan, Ann Arbor, United States
5 Corewell Health, Royal Oak, Michigan, United States
6 University of Michigan, Ann Arbor, United States
7 Henry Ford Health System, Detroit, Michigan, United States
8 Henry Ford Health System, Detroit, Michigan, United States
9 University of Michigan, Ann Arbor, United States
10 University of Michigan, Ann Arbor, United States
11 Trinity Health Michigan, Ypsilanti, Michigan, United States
12 Henry Ford Health System, Detroit, Michigan, United States
13 Henry Ford Health System, Detroit, Michigan, United States
14 Henry Ford Health System, Detroit, Michigan, United States
15 University of Michigan, Ann Arbor, United States
16 University of Michigan, Ann Arbor, United States
17 University of Michigan, Ann Arbor, United States
18 University of Michigan, Ann Arbor, United States
ABSTRACT
Background
Apixaban and rivaroxaban are commonly used for venous thromboembolism (VTE) and atrial fibrillation (AF). For acute VTE, both drugs begin with higher initial dosing before transitioning to maintenance dosing: apixaban for 7 days and rivaroxaban for 21 days. We sought to determine whether the higher dosing for VTE was associated with increased bleeding compared with AF dosing.
Methods
We used data from eight health systems of the Michigan Anticoagulation Quality Improvement Initiative registry, which includes a random sample of patients starting long-term oral anticoagulation. Using predefined forms, trained abstractors perform chart reviews at 6-month intervals. Patients newly anticoagulated for VTE or AF from November 2015 to June 2026 were included. Patients with mechanical heart valves, on dual antiplatelet therapy, or with both VTE and AF were excluded.
Propensity-score matching was performed by logistic regression to balance baseline covariates by anticoagulant indication. The apixaban comparison utilized 1:2 greedy matching between VTE and AF patients; the rivaroxaban cohort utilized 1:1 matching. Poisson regression was used to compare event rates. The primary outcome was any bleeding event, including major and non-major bleeding. Data reported at weekly events per 100 patient-years [100PtYr]. Analysis was completed at weekly and monthly levels.
Results
After matching, the apixaban AF and VTE groups contained 749 and 439 patients respectively, with mean age 67.1 years old, 52.9% female, 79.0% white, and 48.1% body mass index [BMI] >30 kg/m2. The rivaroxaban AF and VTE groups each contained 181 patients with mean age 64.5 years old, 49.7% female, 81.5% white and 51.9% BMI >30.
For both VTE cohorts, bleeding rate was significantly higher in month 1 compared to month 2 (Apixaban: 171 vs 86 bleeds/100PtYr, rate ratio 2.0 (95% confidence interval [CI] 1.2-3.5), p=0.01; Rivaroxaban: 135 vs 56 bleeds /100PtYr, rate ratio 2.4 (95% CI 1.3-4.4), p<0.01). There was no difference in bleeding in AF between months 1 and 2.
During the first month of apixaban treatment, all bleeding was lower in the AF compared to VTE group (39 vs 78 bleeds/100PtYr, rate ratio 0.51 (95% CI 0.3-0.85), p=0.01). Bleeding requiring emergency department [ED] visit (5 vs 18 bleeds/100PtYr, rate ratio 0.29 (95% CI 0.09-0.96), p=0.04) and requiring admission (1 vs 6 bleeds/100PtYr, rate ratio 0.15 (95% CI 0.02-1.38), p=0.1 were also lower for matched patients on apixaban for AF compared to VTE during the first month. No significant differences in bleeding or healthcare utilization were observed for months 2 and 3.
Patients on apixaban for VTE had 190, 24, 83, and 47 bleeds/100PtYr the first four weeks of anticoagulation (p<0.01 comparing week 1 to week 2, p<0.001 for trend over 12 weeks). In comparison, patients on apixaban for AF had 28, 49, 28 and 42 bleeds/100PtYr for the first four weeks of anticoagulation (p=0.55 comparing week 1 to week 2, p=0.55 for trend over 12 weeks).
Bleeding was similar the first month of rivaroxaban treatment for AF compared to VTE (106 vs 133 bleeds/10PtYr, rate ratio 0.80 (95% CI 0.43-1.49), p=0.47. Month 1 bleeding events requiring ED visit or admission were also similar between groups. All bleeding rates were also similar for months 2 and 3, but low event rates limited comparison by subtype.
Patients on rivaroxaban for VTE had 172, 144, 259, and 58 bleeds/100PtYr the first four weeks of anticoagulation (p=0.065 comparing week 3 to week 4, p<0.001 for trend over 12 weeks). Patients on rivaroxaban for AF had 86, 86, 172, and 115 bleeds/100 patient years the first four weeks of anticoagulation (p=0.75 comparing week 3 to week 4, p=0.48 for trend over 12 weeks).
Conclusions
For both apixaban and rivaroxaban for VTE, there was a significantly higher rate of bleeding in month 1 vs month 2, which did not occur in AF groups. The higher initial dosing of apixaban for VTE is associated with a higher rate of bleeding compared to apixaban for AF. A similar trend was observed with rivaroxaban for VTE compared to rivaroxaban for AF but did not reach statistical significance. At a granular level, the highest bleeding rate on apixaban for VTE occurred during week 1 and the highest rate of rivaroxaban for VTE events during weeks 1-3; overlapping with their respective higher dose periods. Overall, this work provides clinically relevant data on the early bleeding risk in anticoagulation initiation.
DISCLOSURES
Steven Grzegorski, MD,PhD: No relevant conflicts of interest to declare.